![](https://menafn.com/includes/img/logo.jpg)
European Commission Approves CSL's ANDEMBRY® (Garadacimab) For The Prevention Of Recurrent Attacks Of Hereditary ...
(MENAFN- PR Newswire) - ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the …